CoChat

New Management Strategy of Pregnancies at Risk of Congenital Adrenal Hyperplasia Using Fetal Sex Determination in Maternal Serum: French Cohort of 258 Cases (2002–2011)

The DOI matches its Crossref record; 40 of the 44 references it cites were found in a registry or an index.

Abstract

CONTEXT: Prenatal dexamethasone (DEX) treatment has been proposed since 1984 to prevent genital virilization in girls with congenital adrenal hyperplasia (CAH). DEX is effective in CAH females if initiated before the sixth week of gestation, but its safety in children treated in utero remains controversial regarding cognitive functions. OBJECTIVE: To avoid prenatal DEX in males and initiate DEX in due time in CAH females, we proposed in 2002 a protocol for fetal sex determination in the maternal serum (SRY test). DESIGN AND SETTING: We conducted a retrospective study of the management of 258 fetuses in the period 2002 through 2011 in pregnancies managed in referent medical centers with an institutional practice. PATIENTS: A total of 258 fetuses at risk of CAH (134 males and 124 females) were included. INTERVENTION: DEX was offered after informed consent to pregnant women. MAIN OUTCOME MEASURE: The sensitivity of an early SRY test was evaluated after data collection. RESULTS: The SRY test is sensitive from 4 weeks and 5 days of gestation. It avoided prenatal DEX in 68% of males, and this percentage increased over the years. DEX was maintained until prenatal diagnosis in non-CAH females. Virilization was prevented in 12 CAH girls treated at the latest at 6 weeks gestation and minimized in 3 girls treated between 6 and 7 weeks gestation. Maternal tolerance was correct. No fetal malformations were noted in the 154 children treated in utero. CONCLUSIONS: The SRY test is reliable to avoid prenatal DEX in males, but its application must be improved. Prenatal DEX should be maintained to prevent virilization and traumatic surgery in CAH girls after informed consent and information provided to families about the benefit to risk ratio in limiting hyperandrogenism during fetal life. Our large multicentric French cohort has helped to better assess the risks previously reported.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2013-2895

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. Gorduza D, Vidal I, Birraux J, et al. The surgical challenges of dis- orders of sex development (DSD). Arch Esp Urol. 2010;63:495- 504.
  2. Tardy V. Management of pregnancies at risk of 21-hydroxylase or 11-hydroxylase deficiency using fetal sex determination in maternal serum proposed in France since 2002: how to limit prenatal expo- sure to dexamethasone. Horm Res. 2009;70(Suppl 3):348.

Cited by

See all 98

Metadata

Authors
Tardy-Guidollet, V., Menassa, R., Costa, J.-M., David, M., Bouvattier-Morel, C., Baumann, C., Houang, M., Lorenzini, F., Philip, N., Odent, S., Guichet, A., & Morel, Y.
Affiliations
  • Hospices Civils de Lyon (FR)
  • Département de Génétique (J.-M.C), Laboratoire Cerba, 95066 Cergy Pontoise, France;
  • Hôpital Femme Mère Enfant (FR)
  • Unité d'Endocrinologie pédiatrique (C.B.-M.), Centre Hospitalier de Bicêtre, 94275 Le Kremlin-Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France;
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Hôpital Armand-Trousseau (FR)
  • Hôpital Paule de Viguier (FR)
  • Assistance Publique Hôpitaux de Marseille (FR)
  • Département de Génétique (S.O.), Hôpital Sud, 35203 Rennes, France;
  • Centre Hospitalier Universitaire d'Angers (FR)
Corresponding author
Tardy-Guidollet, Véronique
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2014-04-01
Volume
99
Issue
4
Pages
1180-1188
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2064123952
Cited by
96
References
44
Citations by year
2026: 4 · 2025: 9 · 2024: 4 · 2023: 6 · 2022: 8 · 2021: 4 · 2020: 6 · 2019: 5 · 2018: 13 · 2017: 7 · 2016: 11 · 2015: 14 · 2014: 4
FWCI
4.92
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Screening and Diagnostics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
congenital adrenal hyperplasia, prenatal dexamethasone, fetal sex determination, SRY gene, maternal serum, prenatal diagnosis, hyperandrogenism, pregnancy management
MeSH terms
Adrenal Hyperplasia, Congenital, Blood Chemical Analysis, Dexamethasone, Female, France, Humans, Male, Maternal-Fetal Exchange, Pregnancy, Prenatal Diagnosis, Risk Factors, Sex Determination Analysis, Virilism, Cohort Studies, Fetal Therapies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.